"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

Efimosfermin showed promise in reducing liver fat and maintaining safety across multiple doses in adults with phenotypic MASH ...

London: GSK plc has concluded the acquisition of efimosfermin alfa from Boston Pharmaceuticals in a USD 2 billion ...

GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...

LONDON - GSK plc (LSE/NYSE:GSK) has completed its acquisition of efimosfermin alfa from Boston Pharmaceuticals, the company announced Monday. The deal, valued at up to $2 billion, includes an ...

Efimosfermin will significantly expand our hepatology pipeline and provide us the opportunity to develop a new potential best-in-class medicine with first launch expected in 2029.

Efimosfermin is described as a phase III-ready, investigational specialty medicine intended for the treatment and prevention of progression of steatotic liver disease (SLD), including metabolic ...

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal.

Efimosfermin is a key growth opportunity for GSK with multiple development options and potential first launch in 2029.” GSK indicated that the addition of efimosfermin expands its pipeline for ...